November 07, 2023
1 min watch
Save
VIDEO: Perioperative pembrolizumab regimen seems ‘practice changing’ for early-stage NSCLC
MADRID — In this video, Julia Rotow, MD, highlighted positive OS data from the KEYNOTE-671 study of a perioperative pembrolizumab regimen for early-stage non-small-cell lung cancer presented at ESMO Congress.
“I firmly expect this to be a practice-changing option for our patients when I return to clinic,” Rotow, clinical director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, said of the pembrolizumab (Keytruda, Merck) regimen.
Reference:
- Spicer JD, et al. Abstract LBA56. Presented at: European Society for Medical Oncology Congress; Oct. 20-24, 2023; Madrid.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Rotow reports numerous ties to industry.
Read more about